COVID-19 Vaccines: EUA Route Offers Advantage In Review Speed, Not Level Of Evidence
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.
You may also be interested in...
Guidance's release would provide regulatory clarity to scientists and strengthen public confidence in any vaccine authorized by the FDA, trade group says, but Alex Azar tells Congress the controversy over the unpublished document is overblown and making a ‘mountain out of a molehill.'
Biologics license application is preferred route to market, but if emergency authorization is given it should happen with full transparency and be communicated in a clear manner to strengthen public confidence, National Vaccine Advisory Committee says.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.